// App-Quantinova.ai

: The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption

Researchers

Presenter

  • Margaret V. Ragni

Principal Investigators

  • Michael Desmond Creagh

  • Toshko Jelev Lissitchkov

  • Steve K. Austin

  • Charles Richard Morris Hay

  • Inga Hegemann

  • Syed Rashid Saeed Kazmi

  • Pratima Chowdary

  • Savita Rangarajan

  • Meredith C. Foster

  • Qifeng Yu

  • Craig Benson

  • Kate Madigan

  • Huy Van Nguyen

  • Shariq Ali

  • Ketaki Kadam

  • Pallavi Jain

  • K. John Pasi

Medical Centers

  • Critical Care Medicine and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA

  • University Multiprofile Hospital for Active Treatment “Sveti Georgi”, and Medical University , Plovdiv, Bulgaria

  • Royal Cornwall Hospital, Truro, United Kingdom

  • Clinical Hematology Clinic Specialized Hospital for Active Treatment of “Joan Pavel”, Sofia , Bulgaria

  • St George's Healthcare NHS Trust Haemophilia Centre, London, United Kingdom

  • Manchester Royal Infirmary, Manchester, United Kingdom

  • University Hospital Zurich

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • Haemophilia & Thrombosis Centre, Royal Free Hospital, London

  • Haemophilia, Haemostasis & Thrombosis Centre, Hampshire Hospitals NHS Foundation Trus, Basingstoke, United Kingdom

  • Sanofi Genzyme, Cambridge, USA

  • Merrimack Pharmaceuticals, Cambridge, MA

  • Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, United Kingdom

Locations

  • United States

  • Bulgaria

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Hemostatic Solution

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved